These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38408937)

  • 21. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial.
    Hoobehfekr S; Moghaddam HS; Shalbafan M; Hashemi MG; Pirmoradi MM; Sakenian A; Poopak A; Kashefinejad S; Yarahmadi M; Akhondzadeh S
    Psychiatry Clin Neurosci; 2021 Feb; 75(2):57-62. PubMed ID: 33247483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
    Barnes TR; Leeson VC; Paton C; Costelloe C; Simon J; Kiss N; Osborn D; Killaspy H; Craig TK; Lewis S; Keown P; Ismail S; Crawford M; Baldwin D; Lewis G; Geddes J; Kumar M; Pathak R; Taylor S
    Health Technol Assess; 2016 Apr; 20(29):1-46. PubMed ID: 27094189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2004; 4(7):1-98. PubMed ID: 23074457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Mathews M; Gommoll C; Chen D; Nunez R; Khan A
    Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder.
    Iovieno N; Shelton RC; Petrie SR; Cusin C; Fava M; Papakostas GI
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 28749091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Tianeptine 25-50 mg in Elderly Patients With Recurrent Major Depressive Disorder: An 8-Week Placebo- and Escitalopram-Controlled Study.
    Emsley R; Ahokas A; Suarez A; Marinescu D; Dóci I; Lehtmets A; Milanova V; Lee MS; Didi R; Araszkiewicz A; Sulaiman AH; Blanchot FP; Crutel VS; Antoine C; Penelaud PF
    J Clin Psychiatry; 2018 Jul; 79(4):. PubMed ID: 29995359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.
    Sepanjnia K; Modabbernia A; Ashrafi M; Modabbernia MJ; Akhondzadeh S
    Neuropsychopharmacology; 2012 Aug; 37(9):2093-100. PubMed ID: 22549115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
    McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
    Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial.
    Araminia B; Shalbafan M; Mortezaei A; Shirazi E; Ghaffari S; Sahebolzamani E; Mortazavi SH; Shariati B; Ardebili ME; Aqamolaei A; Naderi S; Akhondzadeh S
    J Affect Disord; 2020 Apr; 267():131-136. PubMed ID: 32063564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
    Mowla A; Kardeh E
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):970-3. PubMed ID: 21291943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study.
    Amidfar M; Khiabany M; Kohi A; Salardini E; Arbabi M; Roohi Azizi M; Zarrindast MR; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    J Clin Pharm Ther; 2017 Feb; 42(1):44-50. PubMed ID: 27809351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life.
    Ford AH; Flicker L; McCaul K; van Bockxmeer F; Hegarty S; Hirani V; Fenner S; Almeida OP
    Trials; 2010 Jan; 11():8. PubMed ID: 20096138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial.
    Zeinoddini A; Sorayani M; Hassanzadeh E; Arbabi M; Farokhnia M; Salimi S; Ghaleiha A; Akhondzadeh S
    Depress Anxiety; 2015 Mar; 32(3):167-73. PubMed ID: 25620378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation of citalopram with aspirin for treating major depressive disorder, a double blind randomized placebo controlled clinical trial.
    Ghanizadeh A; Hedayati A
    Antiinflamm Antiallergy Agents Med Chem; 2014; 13(2):108-11. PubMed ID: 25091820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.